Trial Profile
A randomised, double blind, placebo controlled, multicentre trial of abagovomab maintenance therapy in patients with epithelial ovarian cancer after complete response to first line chemotherapy.
Status:
Discontinued
Phase of Trial:
Phase II/III
Latest Information Update: 31 Dec 2021
Price :
$35
*
At a glance
- Drugs Abagovomab (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Acronyms MIMOSA
- Sponsors Menarini Ricerche
- 24 Dec 2021 This trial has been completed in Czech Republic (Global end date: 30 Dec 2010).
- 11 Mar 2013 Results published in the Journal of Clinical Oncology.
- 23 Nov 2011 Planned End Date changed from 1 Dec 2015 to 1 Jun 2011 as reported by ClinicalTrials.gov.